Processa Pharmaceuticals Competitors and Similar CompaniesClear all
Processa Pharmaceuticals's competitors and similar companies include Nektar Therapeutics, Takeda, Exelixis and Prolong Pharmaceuticals.
 Processa Pharmaceuticals Processa Pharmaceuticals (formerly Heatwurx) is a company focused on developing treatments for patients with an unmet medical need. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Prolong Pharmaceuticals Prolong Pharmaceuticals is a company providing SANGUINATE, a medication focusing on treating sickle cell disease and other disorders caused by anemia, hypoxia, or ischemia. | |||
Founding Date | Founding Date 2017 | Founding Date 1990 | Founding Date 1781 | Founding Date 1994 | Founding Date 2005 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Hanover, US HQ | Locations San Francisco, US HQ Hyderabad, IN Huntsville, US | Locations Alameda, US HQ | Locations South Plainfield, US HQ | |
Employees | Employees 1033% decrease | Employees 61821% increase | Employees 47,4554% decrease | Employees 1,14712% decrease | Employees 225% increase |
Valuation ($) | Valuation ($) 4.4 m | Valuation ($) 233.8 m | Valuation ($) 43.7 b | Valuation ($) 8.2 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $55.2m (FY, 2025) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods $83.7m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit $2.2b (FY, 2025) | Gross profit N/A |
Net income | Net income ($13.6m) (FY, 2025) | Net income ($164.1m) (FY, 2025) | Net income ¥108.1b (FY, 2025) | Net income $782.6m (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 1 (Oct, 2020) | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 2 (Oct, 2020) | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 45m | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 30m |
For sources of this data, please see the company profile
View Company Profiles
Nektar Therapeutics
HQ
San Francisco, US
Employees
618↑ 21% increase
Nektar Therapeutics is a stage-clinical biopharmaceutical company.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company
Exelixis
HQ
Alameda, US
Employees
1,147↓ 12% decrease
Exelixis is an oncology company that develops cancer treatments.
View companyProlong Pharmaceuticals
HQ
South Plainfield, US
Employees
22↑ 5% increase
Prolong Pharmaceuticals is a company providing SANGUINATE, a medication focusing on treating sickle cell disease and other disorders caused by anemia, hypoxia, or ischemia.
View company